標(biāo)題: Titlebook: Resistance to Immunotherapeutic Antibodies in Cancer; Strategies to Overco Benjamin Bonavida Book 2013 Springer Science+Business Media New [打印本頁(yè)] 作者: 珍珠無(wú) 時(shí)間: 2025-3-21 16:46
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer影響因子(影響力)
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer影響因子(影響力)學(xué)科排名
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer被引頻次
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer被引頻次學(xué)科排名
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer年度引用
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer年度引用學(xué)科排名
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer讀者反饋
書(shū)目名稱Resistance to Immunotherapeutic Antibodies in Cancer讀者反饋學(xué)科排名
作者: 一致性 時(shí)間: 2025-3-21 21:51
Emily L. Williams,Sean H. Lim,Stephen A. Beers,Peter W. Johnson,Jonathan C. Strefford,Martin J. Glenonen, die mit Formen arbeiten.Bildet eine ideale Brücke von .Die ?Geometrie und ihre Anwendungen“ ist für Personen geschrieben, die von relativ einfachen Problemen der ebenen Geometrie bis hin zu schwierigeren Aufgaben der Raumgeometrie Interesse an geometrischen Zusammenh?ngen haben..?hnlich wie be作者: Factual 時(shí)間: 2025-3-22 01:37 作者: 依法逮捕 時(shí)間: 2025-3-22 07:33 作者: Desert 時(shí)間: 2025-3-22 10:41 作者: 擁擠前 時(shí)間: 2025-3-22 12:56
Peter Hersey,Stuart Gallagher,Branka Mijatovund Grundschulalter zugeschrieben. Das Projekt . widmet sich daran anknüpfend der übergeordneten Frage, wie individuelle Vorgehensweisen bei der Erstellung konkreter Bauwerke mit den r?umlichen Vorstellungen von Vor- und Grundschulkindern zusammenh?ngen. Im vorliegenden Beitrag werden theoretische B作者: Capitulate 時(shí)間: 2025-3-22 19:37 作者: byline 時(shí)間: 2025-3-22 22:17 作者: preeclampsia 時(shí)間: 2025-3-23 02:12
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Thenovel therapeutic strategies to overcome or circumvent rituximab-resistance in B-cell lymphoma. Pre-clinical models to study rituximab-resistance have been generated and characterized. Moreover, repeated exposure of lymphoma cells to rituximab, not only results in a decrease in rituximab anti-tumor 作者: Arable 時(shí)間: 2025-3-23 08:43
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototmalignant and malignant B cells. Rituximab is currently the standard therapy when used in combination with chemotherapy (CHOP). However, like other therapeutics, a subset of patients initially does not respond and a subset responding patients develops resistance to further treatments. Such patients 作者: hair-bulb 時(shí)間: 2025-3-23 11:56 作者: Antagonism 時(shí)間: 2025-3-23 15:02 作者: 即席 時(shí)間: 2025-3-23 21:23 作者: COMA 時(shí)間: 2025-3-24 00:48 作者: collateral 時(shí)間: 2025-3-24 05:18
Yangyang Wang,Francesco Sabbatino,Ling Yu,Elvira Favoino,Xinhui Wang,Matteo Ligorio,Soldano Ferrone,作者: condone 時(shí)間: 2025-3-24 08:15 作者: 大約冬季 時(shí)間: 2025-3-24 10:48 作者: 諂媚于人 時(shí)間: 2025-3-24 16:23
Emily L. Williams,Sean H. Lim,Stephen A. Beers,Peter W. Johnson,Jonathan C. Strefford,Martin J. Glenhat die Raumvorstellung Vorrang. Das Buch kann daher auch von Personen ohne spezielle mathematische Vorbildung gelesen werden. .Die 3. Auflage ist um gut 60 Seiten erweitert und enth?lt zahlreiche neue Anwendungen mit hochwertigen Grafiken. .978-3-642-41852-5作者: Verify 時(shí)間: 2025-3-24 21:06
Francisco J. Hernandez-Ilizaliturri,Myron S. Czuczmanhat die Raumvorstellung Vorrang. Das Buch kann daher auch von Personen ohne spezielle mathematische Vorbildung gelesen werden. .Die 3. Auflage ist um gut 60 Seiten erweitert und enth?lt zahlreiche neue Anwendungen mit hochwertigen Grafiken. .978-3-642-41852-5作者: Gentry 時(shí)間: 2025-3-25 02:37
Benjamin BonavidaKonzept mitgeliefert.?.Zwei praktische Kurse runden das Werk ab: zum geometrischen Freihandzeichnen und zur Geometrie des Fotografierens. Leicht verst?ndliche Tipps sollen den Leser zur F?higkeit hinführen, selbstst?ndig pr?gnante und korrekte Raumskizzen zu machen, die der Schlüssel für alles tiefe作者: voluble 時(shí)間: 2025-3-25 03:38 作者: bronchiole 時(shí)間: 2025-3-25 08:24 作者: 相容 時(shí)間: 2025-3-25 15:09 作者: 債務(wù) 時(shí)間: 2025-3-25 16:34 作者: 助記 時(shí)間: 2025-3-25 20:14
Resistance to Targeted Anti-Cancer Therapeuticshttp://image.papertrans.cn/r/image/828452.jpg作者: Connotation 時(shí)間: 2025-3-26 00:37
https://doi.org/10.1007/978-1-4614-7654-2Rituximab; antibody-drug conjugates; cancer drug resistance; mABs; monoclonal antibody; antibodies作者: 馬具 時(shí)間: 2025-3-26 08:13
978-1-4899-8732-7Springer Science+Business Media New York 2013作者: neutrophils 時(shí)間: 2025-3-26 10:13
Resistance to Immunotherapeutic Antibodies in Cancer978-1-4614-7654-2Series ISSN 2196-5501 Series E-ISSN 2196-551X 作者: impale 時(shí)間: 2025-3-26 16:15
2196-5501 etic mechanisms of resistance by various mAbs.Covers the pot????The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encourag作者: 賠償 時(shí)間: 2025-3-26 19:14
Resistance to Anticancer Antibodies: From Mechanisms to Solutions,f resistance to monoclonal antibody therapy. In this review, we discuss the available data for three of the best described antibodies, rituximab, trastuzumab and cetuximab. A variety of approaches and strategies has been suggested or are currently being tested to circumvent resistance to these antibodies.作者: 斜谷 時(shí)間: 2025-3-26 23:00
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics,tor mechanisms of action may provide avenues to combat resistance. The ability to encode unnatural amino acids allows unique site-specific drug conjugates as well as multispecific molecules to be made and developed against HER2-dependent tumors. This broad-based technology could potentially be applied to any antibody therapeutic target.作者: Regurgitation 時(shí)間: 2025-3-27 02:03
Book 2013ntigens and induce an immunological response against the target cancer cell. The book covers?the common?and unique features of mAbs agains various cancer,?gives the latest developments on?the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.作者: 勛章 時(shí)間: 2025-3-27 05:44
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease provide. evidence to suggest that disease recurrence is caused by the lack of eradication of CICs by the TA-specific mAb-based immunotherapy. In addition, we will describe potential strategies to overcome this resistance mechanism which is a major obstacle to the successful application of TA-specific mAb-based immunotherapy.作者: 態(tài)度暖昧 時(shí)間: 2025-3-27 12:45 作者: Trigger-Point 時(shí)間: 2025-3-27 13:54 作者: 卜聞 時(shí)間: 2025-3-27 18:24 作者: LARK 時(shí)間: 2025-3-27 22:24
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Diseaseowever, its efficacy is limited by the lack of response in some of the treated patients and by disease recurrence. In this chapter, following a short description of the characteristics of cancer initiating cells (CICs) and the markers used for their identification in various types of cancer, we will作者: Libido 時(shí)間: 2025-3-28 04:10
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors,ers the prospect of increased potency through antibody engineering or adjuvant therapy. Although roles for complement and the induction of direct cell death remain controversial, the importance of Fc gamma receptors (FcγR) to the efficacy of therapeutic antibodies is irrefutable. However, the biolog作者: Inferior 時(shí)間: 2025-3-28 06:14 作者: foliage 時(shí)間: 2025-3-28 11:58
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Protot therapies against infectious diseases and cancer. However, the practical application of antibody-mediated therapies was only possible several decades later. Porter [155] and Edelman et al. [156] published the molecular structure of the immunoglobulin molecule and through the ingenuity of Kohler and作者: 同步左右 時(shí)間: 2025-3-28 16:21
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer, been proven that patients with mutations in exon 2 of the . ongogene gain no benefit from treatment with the monoclonal antibodies (moAbs) against Epidermal Growth Factor Receptor (EGFR), cetuximab and panitumumab. Currently, the determination of . mutational status represents a paradigm for biomar作者: 憤憤不平 時(shí)間: 2025-3-28 18:56 作者: 切碎 時(shí)間: 2025-3-29 02:15 作者: Resection 時(shí)間: 2025-3-29 06:02 作者: 詞匯 時(shí)間: 2025-3-29 08:39
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistanceer component provides the ADC with an antibody’s exquisite selectivity for its target antigen, which is typically a cell surface molecule with a tumor-restricted expression pattern. The latter component provides the ADC with a highly potent cytotoxic payload that can efficiently kill targeted cells
